Marengo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.marengotx.com
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
- Interventions
- Drug: Sacituzumab Govitecan (SG)
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Marengo Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06827613
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Genital Neoplasm, FemaleUrogenital NeoplasmsLung NeoplasmNeoplasms by SitePapillomavirus InfectionEpstein-Barr Virus InfectionsAdvanced Solid TumorsCarcinomaNeoplasmsVulvar Neoplasms
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Marengo Therapeutics, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT05592626
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇫🇷Institut Bergonié, Bordeaux, France
🇪🇸START Madrid FJD, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath